AustinPx Names Derek Hennecke and Marshall Crew to its Board of Directors
Austin, TX, October 18, 2022 — AustinPx, Pharmaceutics and Manufacturing, a contract development and manufacturing organization (CDMO), today announced the appointment of Derek Hennecke and Marshall Crew as independent members of its board of directors. Appointments provide additional experienced CDMO leadership to drive growth in the complex formulation and manufacturing market
"I am pleased to welcome Derek and Marshall to the board of AustinPx, two seasoned CDMO leaders with broad expertise,” said Tim Scott, president and chief executive officer and member of the board of AustinPx. “Derek’s experience building successful global businesses, including founding and leading early phase oral drug development, manufacturing and clinical supply companies, is the perfect expertise to help us direct the growth of AustinPx’s commercial and market strategies. Marshall’s long history applying amorphous dispersion technologies and his experience founding and running a successful pharmaceutical spray drying company, is the exact perspective we need to take the KinetiSol® Technology to the next level and represents a stamp of approval on the potential of our amorphous dispersion technology.”
Mr. Hennecke currently serves on several boards, he’s a chairman of the board of Microsize and Particle Dynamics and board director of Grand River Aseptic Manufacturing, Inceptor Bio, Kineticos Disruptor Fund, and the Friedreich’s Ataxia Research Alliance. Previously, he was founder and chief executive officer of Xcelience (acquired by Capsugel, now Lonza), board director of Oragenics, vice president and general manager of MDS Pharma Services, and held various leadership roles at DSM Biologics, DSM Anti-Infectives, and Gist-Brocades in the Netherlands, Mexico, and Egypt.
Dr. Crew was cofounder and CEO of Agere, a CDMO specializing in spray dried dispersions and oral bioavailability of poorly soluble molecules that was acquired by Patheon in 2015. Following Agere’s acquisition, he remained with Patheon as vice president of Pharmaceutical Development Services Scientific Excellence, then senior vice president of Innovation. Following the acquisition of Patheon by Thermo Fisher Scientific, Marshall was appointed group vice president and head of strategy, leading the growth activities for the Pharma Services Group. Dr. Crew currently serves on the boards of BioIVT, Formulated Solutions, and Selkirk Pharma.
"We are pleased to welcome Derek and Marshall to the AustinPx Board, bringing proven CDMO expertise that will be invaluable as directors," said Shaun Kirkpatrick, president at Research Corporation Technologies Partners and board chair of AustinPx. "The addition of Derek and Marshall, alongside Tim – three founding leaders of commercially successful CDMOs that helped launch the widespread use of amorphous spray drying and other technologies – further demonstrates our commitment to AustinPx’s growth and the realization of the full market potential of KinetiSol Technology, our next generation amorphous dispersion platform.“
AustinPx, Pharmaceutics and Manufacturing is a contract development and manufacturing organization (CDMO) providing analytical and formulation development services and cGMP manufacturing for small molecule drugs. The Company specializes in phase-appropriate development strategies, speed to clinic and market strategies, and bioavailability enhancement of poorly soluble molecules – including its next generation amorphous dispersion platform, KinetiSol®. AustinPx’s lead investors include Research Corporation Technologies, Inc. and Acadia Woods. For more information, visit www.AustinPx.com.